Palladium(II) and ruthenium(II) complexes of benzotriazole functionalized N-heterocyclic carbenes: Cytotoxicity, antimicrobial, and DNA interaction studies

dc.authorid0000-0001-5009-3223
dc.authorid0000-0003-3371-9874
dc.authorid0000-0003-0724-4772
dc.authorid0000-0002-4085-0224
dc.authorid0000-0001-6080-229X
dc.contributor.authorOnar, Gulnihan
dc.contributor.authorGurses, Canbolat
dc.contributor.authorKaratas, Mert Olgun
dc.contributor.authorBalcioglu, Sevgi
dc.contributor.authorAkbay, Nuriye
dc.contributor.authorOzdemir, Namik
dc.contributor.authorAtes, Burhan
dc.date.accessioned2025-05-10T19:50:23Z
dc.date.issued2019
dc.departmentİstanbul Medeniyet Üniversitesi
dc.description.abstractIn the present study, four palladium and four ruthenium complexes were synthesized with benzotriazole substituted N-heterocyclic carbene ligands. The structures of complexes were established by appropriate spectroscopic methods and elemental analyses. In addition, the crystal structure of a Pd-NHC complex (1c) was reported. Anticancer, antimicrobial and DNA interaction properties of the complexes were examined. Antimicrobial effects of the complexes were tested against two bacteria strains and one fungi strain. Cytotoxic effects of the complexes were tested against human breast (MCF-7) and colorectal (Caco-2) cancer cell lines and non-cancer mouse fibroblast (L-929) cell lines. Ruthenium complexes were found as more cytotoxic than palladium complexes against cancer cell lines. Especially, benzyl containing, benzimidazole-based ruthenium complexes (3c and 3d) were found as non-cytotoxic against non-cancer L-929 cell lines while performing comparable cytotoxicity against Caco-2 cancer cell lines with cisplatin. In addition, DNA interaction studies were performed with pBR322 plasmid DNA and ctDNA and results showed that both palladium and ruthenium complexes have weaker ability to interact with DNA than cisplatin. The results from this study showed that although the cytotoxic properties of the complexes are not stronger than cisplatin, selectivity of benzyl containing benzimidazole-based ruthenium-NHC complexes against Caco-2 cell lines provides them an advantage, and they deserve further research in the treatment of human colorectal cancer. (c) 2019 Elsevier B.V. All rights reserved.
dc.identifier.doi10.1016/j.jorganchem.2019.02.013
dc.identifier.endpage56
dc.identifier.issn0022-328X
dc.identifier.issn1872-8561
dc.identifier.scopus2-s2.0-85062170111
dc.identifier.scopusqualityQ2
dc.identifier.startpage48
dc.identifier.urihttps://doi.org/10.1016/j.jorganchem.2019.02.013
dc.identifier.urihttps://hdl.handle.net/20.500.14730/12342
dc.identifier.volume886
dc.identifier.wosWOS:000461174700007
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.language.isoen
dc.publisherElsevier Science Sa
dc.relation.ispartofJournal of Organometallic Chemistry
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WOS_20250302
dc.subjectBenzotriazole
dc.subjectPalladium(II)
dc.subjectRuthenium(II)
dc.subjectN-heterocyclic carbene
dc.subjectAnticancer
dc.subjectAntimicrobial
dc.titlePalladium(II) and ruthenium(II) complexes of benzotriazole functionalized N-heterocyclic carbenes: Cytotoxicity, antimicrobial, and DNA interaction studies
dc.typeArticle

Dosyalar